Scholarlink

Objective <p>Accelerated bone loss is a side effect of many anticancer treatments, posing significant health challenges for cancer survivors. The aim of this systematic review was to evaluate and synthesize recommendations for the management of bone health, specifically fracture and osteoporosis risk, in clinical guidelines for people with cancer.</p> Methods <p>Searches related to bone health clinical guidelines for cancer patients were conducted in four electronic databases (PubMed, EMBASE, CINAHL, and Scopus). Data extraction was performed independently by multiple authors. Quality appraisal was performed using the Appraisal of Guidelines for Research &amp; Evaluation II (AGREE II) instrument. Guidelines were categorized into three key focus areas (pharmacological interventions, screening, and lifestyle modifications) and compared across cancer types.</p> Results <p>A total of sixty-five guidelines were included in the systematic review. Two-thirds of guidelines included recommendations related to lifestyle (most commonly vitamin D and calcium supplementation), 76% related to screening (mostly bone mineral density via DXA), and 89% related to pharmacological intervention (most commonly bisphosphonates and denosumab). Fifty-four percent included recommendations in all three domains. Using the AGREE II tool, 42 guidelines were rated moderate and 23 high with strong scoring in domains of Scope and Purpose, Clarity of Presentation and Editorial Independence.</p> Conclusions <p>Findings highlight variations in guideline quality, with many lacking holistic, multidisciplinary recommendations for bone health management. Further development of guidelines supporting patients impacted by multiple risk factors, and the inclusion of management strategies to mitigate compounding effects of cancer-related bone loss and age-related bone degradation among cancer patients, is recommended.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management of bone health in cancer survivorship: a systematic review of clinical guidelines

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月24日

查看全文
  • Victor Ki Chung Li,
  • Stirling Cosgrove,
  • Katelyn Collins,
  • Paul Baden,
  • Richard Blennerhassett,
  • Bryan A. Chan,
  • Li-Heng Chan,
  • Daphne Day,
  • Belinda Goodwin,
  • Alastair Kwok,
  • Debbie Packham,
  • Kaung Tha Kyaw,
  • Christopher Todaro,
  • Kate Webber,
  • Janne Williams,
  • Ayse Zengin,
  • Lisa Grech

摘要

Objective

Accelerated bone loss is a side effect of many anticancer treatments, posing significant health challenges for cancer survivors. The aim of this systematic review was to evaluate and synthesize recommendations for the management of bone health, specifically fracture and osteoporosis risk, in clinical guidelines for people with cancer.

Methods

Searches related to bone health clinical guidelines for cancer patients were conducted in four electronic databases (PubMed, EMBASE, CINAHL, and Scopus). Data extraction was performed independently by multiple authors. Quality appraisal was performed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. Guidelines were categorized into three key focus areas (pharmacological interventions, screening, and lifestyle modifications) and compared across cancer types.

Results

A total of sixty-five guidelines were included in the systematic review. Two-thirds of guidelines included recommendations related to lifestyle (most commonly vitamin D and calcium supplementation), 76% related to screening (mostly bone mineral density via DXA), and 89% related to pharmacological intervention (most commonly bisphosphonates and denosumab). Fifty-four percent included recommendations in all three domains. Using the AGREE II tool, 42 guidelines were rated moderate and 23 high with strong scoring in domains of Scope and Purpose, Clarity of Presentation and Editorial Independence.

Conclusions

Findings highlight variations in guideline quality, with many lacking holistic, multidisciplinary recommendations for bone health management. Further development of guidelines supporting patients impacted by multiple risk factors, and the inclusion of management strategies to mitigate compounding effects of cancer-related bone loss and age-related bone degradation among cancer patients, is recommended.